David McIntosh: The Growing Global Demand for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Neha Patil‘s post on LinkedIn:
“This is an interesting and informative post.
However, it needs to come with a health warning.
The total effort of all the companies listed here, plus all the others involved, plus the Public and non-profit participants, only add up to a total global plasma-derived medicines availability of less than one quarter of what’s actually required.
Eighty percent or more of the global need for plasma-derived medicines goes unmet.
There is just soooo much more work to do.
This is not to criticise the Industry or any members of it – just to point out that this is not an area for hyperbolic optimism.
It’s a field requiring grim determination to work on improving a thoroughly sub-optimal global situation.”
Neha Patil, Search Engine Optimization Executive at Persistence Market Research (UK), shared a post in the Pharma Business group on LinkedIn:
“The Future of Blood Plasma: Advancing Life-Saving Therapies Through Plasma-Derived Innovation
The blood plasma industry plays a vital role in modern healthcare by enabling the production of plasma-derived therapies for immunology, hematology, neurology, and critical care.
Rising demand for immunoglobulins, increasing plasma collection activities, and continuous advancements in biopharmaceutical manufacturing are driving market growth worldwide.
The global Blood Plasma Market is expected to be valued at US$ 33.5 billion in 2026 and is projected to reach US$ 54.2 billion by 2033, growing at a CAGR of 7.1% between 2026 and 2033.
As demand for plasma-derived medicines continues to increase, the market is evolving through several key trends:
- Growing demand for immunoglobulins, albumin, and coagulation factor therapies
- Increasing investments in plasma collection centers and fractionation technologies
- Rising prevalence of immune deficiencies, bleeding disorders, and rare chronic diseases
- Expanding research and development focused on next-generation plasma-derived therapeutics
Company Details
Biotest – Developing plasma-derived therapies for immunology, hematology, and intensive care applications
GCBiopharma – Expanding plasma protein therapies and innovative biopharmaceutical solutions
Grifols – Advancing plasma-derived medicines through an extensive global plasma collection network
Intas Pharmaceuticals – Strengthening biologics and specialty pharmaceutical capabilities across global markets
Kedrion – Specializing in plasma-derived therapies for rare and life-threatening diseases
LFB – Developing innovative plasma-derived medicinal products for patients with rare disorders
Octapharma – Delivering high-quality plasma proteins and recombinant therapies worldwide
Sanquin – Advancing plasma collection, blood banking, and transfusion medicine innovations
Takeda Pharmaceuticals – Expanding plasma-derived therapies for rare diseases and immunological disorders.”
Other posts featuring David McIntosh on Hemostasis Today.
-
Aug 19, 2026, 13:51Lucie Ellis-Taitt: Why Hemophilia Gene Therapies Are Failing?
-
Aug 19, 2026, 13:46Ahmed Bahi: Improving Hemophilia and Rare Disease Care in the Middle East
-
Aug 19, 2026, 13:34Edward Lee Carter: Can EZPLAZ Bring Plasma to Patients Earlier?
-
Aug 19, 2026, 12:55Maia Meier: When a Rare Bleeding Disorder Changes a Family’s Journey
-
Aug 19, 2026, 12:45Melissa Hollo: Impact of Anemia on Surgical Outcomes
-
Aug 19, 2026, 12:40Wolfgang Miesbach: The Growing Impact of Age-Related Disease in Hemophilia
-
Aug 19, 2026, 12:12Thirunavukkarasu Angappan: The Global Shift Toward Plasma Self-Sufficiency
-
Aug 19, 2026, 09:12Charlie Berman: Infections Following Mechanical Thrombectomy for Acute Stroke
-
Aug 19, 2026, 08:39Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology